Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Skin Neoplasms

• Phase I Study of ANK-101 in Advanced Solid Tumors
• Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
• DETERMINE Trial Treatment Arm 4: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
• Cryoablation+Ipilimumab+Nivolumab in Melanoma
• Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
• Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
• Pilot Trial of Supplemental Vitamin A and Nicotinamide
• Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
• Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
• A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (ANV419-101).
• A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
• Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
• Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
• Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
• L19IL2/L19TNF in Skin Cancer Patients
• Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
• A Phase II Clinical Trial Evaluating Ipilimumab, Nivolumab, and Cabozantinib in Patients With Anti-PD-1(L1) Refractory Cutaneous Melanoma
• Open-Label Proof of Concept Study of LTX-315 in Basal Cell Carcinoma
• Lifileucel and Pembrolizumab for the Treatment of Locally Advanced Stage IIIB-D Melanoma
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
• A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC
• IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
• Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
• A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
• The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma
• Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
• Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)
• Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
• 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
• A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma
• Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
• Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery
• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
• Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
• Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
• Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
• Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
• Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
• A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
• Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
• Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
• Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
• Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
• Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
• Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
• Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
• Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer
• A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin
• Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma
• Neoadjuvant Atezolizumab in Cutaneous Melanoma
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
• Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
• High-Risk Skin Cancers With Atezolizumab Plus NT-I7
• Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
• Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
• Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial
• Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation
• Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
• CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
• Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
• Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
• Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
• A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
• Study of REGN2810 Prior to Surgery in Patients With Advanced-Stage, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
• Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
• Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
• A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
• Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
• Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
• Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
• An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
• A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
• Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
• REO13 Melanoma With of Without GM-CSF
• Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
• Topical Antibiotic Prophylaxis for Eyelids
• Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
• Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
• Preoperative Acetaminophen and Carbohydrate Loading
• DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients
• Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
• Study of Topical SOR007 Ointment for Cutaneous Metastases
• Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
• Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
• Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
• Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)
• Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
• Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
• Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial
• Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma
• A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
• Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
• Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States
• Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy
• HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
• Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
• A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
• Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
• XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
• 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
• Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
• Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
• Topical Chemoprevention of Skin Cancer Biomarkers
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
• Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
• Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
• A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
• Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
• Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies
• MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
• Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
• PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
• Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
• Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
• Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
• Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
• Safety Study of a Fluorescent Marker to Visualize Cancer Cells
• Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
• Biomarker Correlates of Hypoxia in Metastatic Melanoma
• Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
• Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
• Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
• Efficacy of Propranolol Treatment to Prevent Melanoma Progression
• Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
• Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
• Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
• Calcium Electroporation for Treatment of Cutaneous Metastases
• Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
• Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
• Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
• Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours
• Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
• Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
• Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
• Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
• Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
• Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma
• Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
• Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
• Ipilimumab and Imatinib Mesylate in Advanced Cancer
• Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver
• Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
• Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
• Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
• New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)
• Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g
• Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
• Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
• Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer
• Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation
• Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
• Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
• Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI
• Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
• Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer
• Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
• Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
• Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
• Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
• Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
• Can We Miss Pigmented Lesions in Psoriasis Patients?
• Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer
• Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
• Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy
• Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
• Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
• MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
• ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
• CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
• A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
• CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial
• Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer
• Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
• Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer
• Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
• Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer
• Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
• Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
• Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
• Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
• Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery
• Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
• Study of ADI-PEG 20 in Patients With Advanced Melanoma
• Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
• Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
• Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients
• Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
• Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
• Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
• Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
• Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
• Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck
• Use of 852A in Metastatic Cutaneous Melanoma.
• TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
• Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
• Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
• Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
• Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
• Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
• T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
• Study of Talabostat and Cisplatin in Advanced Melanoma
• Study of Talabostat in Advanced Melanoma
• Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer
• S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
• Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer
• ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
• Imatinib Mesylate in Treating Patients With Metastatic Melanoma
• Celecoxib in Preventing Skin Cancer
• Isotretinoin in Preventing Skin Cancer
• Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin
• Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
• Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
• Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
• Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer
• Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer
• SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
• Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer
• Green Tea Extract in Treating Patients With Actinic Keratosis
• Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
• Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
• S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
• Photodynamic Therapy in Treating Patients With Skin Cancer
• Photodynamic Therapy in Treating Patients With Skin Cancer
• Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
• Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
• A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma